SCYNEXIS (NASDAQ:SCYX – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.
SCYNEXIS Price Performance
Shares of SCYX stock opened at $0.93 on Thursday. The business’s fifty day moving average price is $1.08 and its 200 day moving average price is $1.25. SCYNEXIS has a 1-year low of $0.82 and a 1-year high of $3.07. The firm has a market capitalization of $35.37 million, a PE ratio of -1.26 and a beta of 1.67.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last posted its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. The company had revenue of $0.98 million for the quarter. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%.
Institutional Trading of SCYNEXIS
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Further Reading
- Five stocks we like better than SCYNEXIS
- How to Invest in Insurance Companies: A Guide
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.